VC
CAMP icon

Vivo Capital’s CAMP4 Therapeutics CAMP Stock Holding History

Vivo Capital’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6M Hold
4,246,568
– – 1.69% 22
2026
Q1 		$18.7M Hold
4,246,568
– – 1.56% 23
2025
Q4 		$26M Buy
4,246,568
+325,000
+8% +$1.38M 1.68% 20
2025
Q3 		$11.8M Buy
+3,921,568
New +$7.26M 0.95% 28

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vivo Capital's CAMP Position: Q2 2026 in Review

Vivo Capital held its CAMP4 Therapeutics (CAMP) position steady in Q2 2026 at 4,246,568 shares worth $18.6M. The position accounts for 1.69% of the portfolio, ranked #22.

Vivo Capital first reported a position in CAMP in Q3 2025 and has held it in 4 quarters since. The position peaked at $26M in Q4 2025. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Vivo Capital held 4,246,568 shares of CAMP4 Therapeutics worth $18.6M as of Q2 2026.
  • Vivo Capital left its CAMP4 Therapeutics share count unchanged in Q2 2026.
  • CAMP4 Therapeutics made up 1.69% of Vivo Capital's portfolio in Q2 2026, its #22 holding.
  • Vivo Capital first reported a position in CAMP4 Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Vivo Capital's CAMP4 Therapeutics position peaked at $26M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.